In response to WHO's calls for litigation against tobacco companies, Philip Morris International today reiterated its desire for collaboration and an end to destructive confrontation. "Little is accomplished when organizations focus on conflict rather than seeking solutions through engagement with all interested parties", said David R. Davies, Senior Vice President, Corporate Affairs, Philip Morris International.
Philip Morris International has vocally supported the adoption of a global treaty on tobacco control. "We support both international regulation and national regulation, including restrictions on marketing and advertising, minimum age laws, public smoking restrictions, and product regulation. We have repeatedly expressed our desire to work with public health officials, including WHO" said Mr. Davies. Philip Morris International supports an international treaty based on four key principles: a consistent public health message about smoking, effective measures to prevent minors from smoking, the ability of adults to choose to smoke, and a level playing field for all tobacco manufacturers.
Regrettably there are those who seem to have no interest in dialogue, who pursue rhetoric and conflict at the cost of solutions. Their focus is on old documents, past behavior and retribution. "This is not our approach. It is time for this rancour to end and for true progress to begin. This is happening in many countries around the world. It should happen in Geneva", said Mr. Davies. "We understand the very legitimate concerns about smoking, but litigation is not the solution".
PMI is the world’s leading international tobacco company, with six ot the world’s top 15 international brands and products sold in more than 180 markets. In addition to the manufacture and sale of cigarettes, including Marlboro, the number one global cigarette brand, and other tobacco products, PMI is engaged in the developement and commercialization of Reduced-Risk Products (RRPs). RRPs is the term PMI uses to refer to products with the potential to reduce individual risk and population harm in comparison to smoking cigarettes. Through multidisciplinary capabalities in product development, state-of-the-art facilities, and indusrty-leading scientific substantiation, PMI aims to provide an RRP portfolio that meets a broad spectrum of adult smoker preferences and rigorous regulatory requirements.